FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			or Section 30(f) of the investment Company Act of 1940							
1. Name and Add	ress of Reporting F	Person*	2. Issuer Name <b>and</b> Ticker or Trading Symbol Sage Therapeutics, Inc. [SAGE]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
	<u>ODLINI</u>			X Director X 10% Owner						
				Officer (give title Other (specify						
(Last)	(First) (Middle)		3. Date of Earliest Transaction (Month/Day/Year)	below) below)						
8725 WEST H	IIGGINS ROAI	), SUITE 290	07/23/2014							
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applied							
CHICAGO	IL	60631		X Form filed by One Reporting Person						
				Form filed by More than One Reporting Person						
(City)	(State)	(Zip)								
		Table I - Non-	Derivative Securities Acquired, Disposed of, or Bene	ficially Owned						

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (1 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(msu. 4)
Common Stock	07/23/2014		С		1,587,301	A	(1)	1,587,301	Ι	See Footnotes <sup>(4)(5)</sup>
Common Stock	07/23/2014		с		2,380,951	A	(2)	3,968,252	I	See Footnotes <sup>(4)(5)</sup>
Common Stock	07/23/2014		С		281,137	A	(3)	4,249,389	I	See Footnotes <sup>(4)(5)</sup>

 
 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Series A Preferred Stock	(1)	07/23/2014		С			5,000,000	(1)	(1)	Common Stock	1,587,301	(1)	0	I	See Footnotes <sup>(4)(5)</sup>
Series B Preferred Stock	(2)	07/23/2014		С			7,500,000	(2)	(2)	Common Stock	2,380,951	(2)	0	Ι	See Footnotes <sup>(4)(5)</sup>
Series C Preferred Stock	(3)	07/23/2014		С			885,583	(3)	(3)	Common Stock	281,137	(3)	0	Ι	See Footnotes <sup>(4)(5)</sup>

## Explanation of Responses:

1. The Series A Preferred Stock automatically converted into Common Stock on a 3.15-for-1 basis at the closing of the Issuer's initial public offering for no consideration, and had no expiration date

2. The Series B Preferred Stock automatically converted into Common Stock on a 3.15-for-1 basis at the closing of the Issuer's initial public offering for no consideration, and had no expiration date

3. The Series C Preferred Stock automatically converted into Common Stock on a 3.15-for-1 basis at the closing of the Issuer's initial public offering for no consideration, and had no expiration date

4. ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH Venture Fund VII, L.P. ("ARCH"), may be deemed to beneficially own certain of the shares held by ARCH. The GPLP disclaims beneficial ownership of all shares held by ARCH in which the GPLP does not have an actual pecuniary interest. ARCH Venture Partners VII, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held by ARCH. The GPLP disclaims beneficial ownership of all shares held by ARCH in which the GPLP. The GPLP, may be deemed to beneficially own certain of the shares held by ARCH. The GPLP disclaims beneficial ownership of all shares held by ARCH in which it does not have an actual pecuniary interest.

5. (Continued from Footnote 4) The managing directors of the GPLLC, the Reporting Person, Keih Crandell and Clinton Bybee (together, the "Managing Directors"), are deemed to have voting and dispositive power over the shares held by ARCH, and may be deemed to beneficially own certain of the shares held by ARCH. The Reporting Person disclaims beneficial ownership of all shares held by ARCH in which he does not have an actual pecuniary interest.

## Remarks:

/s/ Laurie Burlingame, as

Nelsen

Attorney-in-Fact for Robert T.

07/23/2014

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.